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Letter to the Editor
CORYNEBACTERIUM PARVUM AND METASTATIC BREAST CANCER
SIR,-Immunotherapy has been used as an
experimental treatment of human cancer for
more than a decade. Initial enthusiasm for
this approach was largely based on theoretical
notions about the role ofimmunity in cancer,
the success of immunotherapy in some
animal tumour systems, and early results of
nonspecific immunotherapy in some human
cancers. As an example of the latter, Israel
(1975) reported that nonspecific immuno-
therapy with the killed bacterial vaccine
Corynebacterium parvum (CP) improved sur-
vival in patients with a variety ofcarcinomas,
including carcinomas of the lung and breast.
Unfortunately, subsequent studies with CP in
lung cancer, for example those reported in
your journal by Souter et al. (1981) and
by us (Sarna et al., 1978) have shown no
benefit from CP in patients with this disease.
Negative reports, such as those cited above,
are useful in helping to minimize the exposure
of patients to ineffective treatment. It is for
this reason that we report here additional
negative results with CP from a randomized
clinical trial in metastatic breast cancer. In
this trial we used the same dose, route and
schedule of CP administration that had been
reported by Israel (1975) to see whether it
would improve the survival of patients with
metastatic breast cancer andreceiving chemo-
therapy. Thirty-two patients with progres-
sive, hormone unresponsive metastatic breast
cancer were entered into this trial between
June 1976 and November 1978. They all
received doxorubicin (40 mg/M2) i.v. on
Day 1 and cyclophosphamide (200 mg/M2)
orally on Days 3-6 of each monthly course,
as described by Jones et al. (1975). They also
gave informed consent for randomization to
receive in addition either a weekly s.c.
injection of sterile water or CP (Burroughs
Wellcome Co.) 2x5 mg/M2, until objective
tumour progression or death.
The 2 groups were similar in terms of age,
disease-free interval, oestrogen-receptor
status, sites ofmetastases, and prior therapy.
Twenty-nine of 30 patients evaluable for
response had stabilization of disease lasting
at least 6 months, or a partial response (at
least 50% decrease in cross sectional area of
measurable tumour). Only one patient had
early progression. Toxicity was similar in
the 2 groups, save for the development of
local skin inflammation at sites of CP
administration. One patient discontinued CP
because ofsevere skin ulceration at the site of
s.c. injection. There was no difference
between the groups in the intensity or
duration of nausea, vomiting, or leukopenia
All the patients developed alopecia. One
patient developed congestive heart failure
while receiving doxorubicin, cyclophospha-
mide, and CP.
At the time of writing 26/32 patients had
died, and the survival curves for the 2 groups
were not significantly different using the
generalizedWilcoxon (Breslow) test (P= =100)
or the generalized Savage (Mantel-Cox) test
(P=0.89). The survival curves for patients
with a partial response were similarly indis-
tinguishable.
We conclude that s.c. CP did not increase
the duration of survival in our patients with
metastatic breast cancer, just as the i.v.
route had failed in metastatic lung cancer
(Sarna et al., 1978). Although our patient
population was too small to rule out a "type
2" statistical error, our assessment of the
relative risks and benefits of this agent in
this and a previous breast-cancer trial
(Haskell et al., 1977) has led us to abandon
its use in patients with metastatic disease.
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